CSPC announced in Hong Kong that the nidanib ethanesulfonate inhalation powder developed by the Group has been approved by the China National Drug Administration and can conduct clinical trials in China. This product is the first inhalation preparation approved for clinical use in China to treat pulmonary fibrosis. Nidanib ethanesulfonate is a multiple tyrosine kinase inhibitor that can slow the progression of idiopathic pulmonary fibrosis. The dosage form currently on the market is an oral softgel.

CSPC announced in Hong Kong that the nidanib ethanesulfonate inhalation powder developed by the Group has been approved by the China National Drug Administration and can conduct clinical trials in China. This product is the first inhalation preparation approved for clinical use in China to treat pulmonary fibrosis. Nidanib ethanesulfonate is a multiple tyrosine kinase inhibitor that can slow the progression of idiopathic pulmonary fibrosis. The dosage form currently on the market is an oral softgel.